The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2023 | The clinical use of circulating tumor DNA in T-cell lymphomas
Jasmine Zain, MD, City of Hope, Duarte, CA, discusses ongoing research investigating the clinical utility of circulating tumor DNA (ctDNA) to detect measurable residual disease (MRD) in T-cell lymphomas. Dr Zain highlights various markers being explored, such as T-cell receptor degradation and markers of apoptosis, before adding that individualized probes may be required to detect patient ctDNA in this disease setting. This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
